Pyxis Oncology follow-on prices 39.7 mln shares and warrants for $110 mln gross
Pyxis Oncology priced a follow-on: ~39.7 mln shares and pre-funded warrants at $2.90 each for $110 mln gross proceeds, plus ~49.3 mln warrants at $3.50 exercise price for additional $172.6 mln if fully exercised.
* Pyxis Oncology's shares down 10.3% at $2.60 before the bell on Weds after follow-on priced * PYXS early Weds announced ~39.7 mln shares and pre-funded warrants at $2.90 for $110 mln gross proceeds * Co also sold accompanying warrants to purchase ~49.3 mln shares at exercise price of $3.50; co would reap additional gross proceeds of $172.6 mln if they are fully exercised * Boston, Massachusetts-based PYXS has ~83.4 mln shares outstanding * It intends to use net offering proceeds to advance lead candidate, micvotabart pelidotin (MICVO), an antibody-drug conjugate to treat solid tumors, and for working capital and general purposes * Leerink Partners, Guggenheim and Wells Fargo are joint bookrunners * PYXS stock closed flat at $2.90 on Tues, but had rallied 152% YTD * 9 of 10 analysts rate the stock "strong buy" or "buy", 1 "hold"; median PT $7, per LSEG (Lance Tupper is a Reuters market analyst.
The views expressed are his own) ((lance.tupper@tr.com 1-646-279-6380)